Epic Tools for Epic Science

As Bio-Techne, we have united multiple brands to provide a unique and comprehensive product portfolio. Together, our brands provide world class products and services for life-science research and clinical applications.

Investor Presentation

Latest Presentation

August 16, 2017

Corporate Presentation June 2017

View Presentation View All

Current

Reportable Segments

  • Biotechnology R&D Systems®, PrimeGene®, Novus Biologicals®, Tocris®
  • Diagnostics R&D Systems®, Cliniqa®, Bionostics®, BiosPacific®
  • Protein Platforms ProteinSimple®, Simple Plex™, Milo™

Revenue

Customer Segmentation

  • Pharma/Biotechnology
  • Academia
  • OEM
  • Distributors

Revenue

Geography

  • Americas
  • EMEA
  • APAC

Latest Quarterly Results

Q1 2018

Quarter Ended Sep 30, 2017

Get Alerts

$145 Million

First Quarter Net Sales

$98 Million

First Quarter Gross Margin

$16 Million

First Quarter Net Income

Sign up for E-Mail Alerts

Sign up today

Latest Annual Highlights

$563M

Fiscal 2017 Net Sales

$121M

Fiscal 2017 Operating Income

$158M

Fiscal 2017 Cash Flow From Operations

View 10-K Get Alerts

Stock Information

Bio-Techne Corporation

NASDAQ: TECH

 |  View Detailed Stock Info

Price
Change
Volume
Day Range
52 Week Range

Company Overview

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins - notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds - which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota.

The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls for OEM customer and clinical customers. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide.

Fast Facts

Net sales (July 2016 to June 2017)

$563 million

Employees Worldwide

~1,800

Products

500,000+

Journal citations

350,000+

Incorporated in Minneapolis, Minnesota

1981

Leadership

Our people are our backbone. Touting years of experience in a variety of fields, our leadership team is a source of our success.

IR Contact Information

Company Information

Corporate Secretary
614 McKinley Place NE
Minneapolis, MN 55413

Investor Relations

David Clair
T: 646-277-1266
ir@bio-techne.com

Transfer Agent

American Stock Transfer
6201 15th Avenue
Brooklyn, NY 11219
T: 800-937-5449
help@astfinancial.com